References
- Costa B, Gonçalves A, Abrantes A, Alves R, Matafome P, Seiça RM, Sarmento-Ribeiro AB, Botelho M, Sousa F. Intestinal Epithelial Stem Cells: Distinct Behavior After Surgical Injury and Teduglutide Administration. J Invest Surg. 2018; 31(3):243–52. [doi: 10.1080/08941939.2017.1294217]
- Schwartz LK, O'Keefe SJ, Fujioka K, Gabe SM, Lamprecht G, Pape UF, et al. Long-Term Teduglutide for the Treatment of Patients With Intestinal Failure Associated With Short Bowel Syndrome. Clin Transl Gastroenterol. 2016;7:e142. [doi: 10.1038/ctg.2015.69. PMID: 26844839]
- Krishnan K, Arnone B, Buchman A. Intestinal growth factors: potential use in the treatment of inflammatory bowel disease and their role in mucosal healing. Inflamm Bowel Dis. 2011;17:410–422. [doi: 10.1002/ibd.21316. PMID: 20848489]
- Garrison AP, Dekaney CM, von Allmen DC, Lund PK, Henning SJ, Helmrath MA. Early but not late administration of glucagon-like peptide-2 following ileo-cecal resection augments putative intestinal stem cell expansion. Am J Physiol Gastrointest Liver Physiol. 2009;296:G643–G650. [doi: 10.1152/ajpgi.90588.2008. PMID: 19118113]
- Booth C, Booth D, Williamson S, Demchyshyn LL, Potten CS. Teduglutide ([Gly2]GLP-2) protects small intestinal stem cells from radiation damage. Cell Prolif. 2004;37:385–400. [PMID: 15548172]
- Intestinal epithelial stem cells. distinct behavior after surgical injury and teduglutide administraton. Journal of Investigative Surgery. In press
- Sipos F, Műzes G. Injury-associated reacquiring of intestinal stem cell function. World J Gastroenterol. 2015;21:2005–2010. [doi: 10.3748/wjg.v21.i7.2005. PMID: 25717233]
- Chaturvedi LS, Basson MD. Glucagonlike peptide 2 analogue teduglutide: stimulation of proliferation but reduction of differentiation in human Caco-2 intestinal epithelial cells. JAMA Surg. 2013;148:1037–1042. [doi: 10.1001/jamasurg.2013.3731. PMID: 24068167]
- Buchman AL, Katz S, Shnaidman M, Jacobs D. Effect of Teduglutide on Patients With Moderate-Severe Crohn's Disease After 8 Weeks of Therapy: A Prospective, Double-Blind, Placebo-Controlled Trial. Gastroenterology. 2006;131:949–950. [DOI: http://dx.doi.org/10.1053/j.gastro.2006.06.097]
- Jaggupilli A, Elkord E. Significance of CD44 and CD24 as cancer stem cell markers: an enduring ambiguity. Clin Dev Immunol. 2012;2012:708036. [doi: 10.1155/2012/708036. PMID: 22693526]
- Gray PC, Vale W. Cripto/GRP78 modulation of the TGF-β pathway in development and oncogenesis. FEBS Lett. 2012;586:1836–1845. [doi: 10.1016/j.febslet.2012.01.051. PMID: 22306319]